InMed Pharmaceuticals Reprices Warrants to $0.80, Potentially Unlocking $1.8M in Capital Amid Going Concern

summarizeSummary

InMed Pharmaceuticals amended preferred investment options held by Sabby and H.C. Wainwright, significantly reducing the exercise price of warrants to $0.80, making them more likely to be exercised and potentially providing critical capital.

check_boxKey Events · Financing and Capital Events · INM

• Warrant Exercise Price Reduced

  The exercise price for preferred investment options held by Sabby Volatility Warrant Master Fund and H.C. Wainwright affiliates was amended to $0.80 per share, down from previous prices ranging up to $82.50.

• Significant Potential Capital Infusion

  This repricing makes over 2.3 million warrants exercisable, potentially generating approximately $1.8 million in proceeds for the company if fully exercised.

• Addresses Going Concern Risks

  The move is a critical step for the company, which has previously disclosed substantial doubt about its ability to continue as a going concern and faces Nasdaq delisting risks.

auto_awesomeAnalysis · INM · Life Sciences

InMed Pharmaceuticals, facing substantial doubt about its ability to continue as a going concern, has repriced a significant number of preferred investment options (warrants) held by Sabby Volatility Warrant Master Fund and H.C. Wainwright affiliates. The exercise price for these warrants, covering over 2.3 million common shares, was drastically reduced from previous levels (ranging from $2.436 to $82.50) to $0.80 per share. This repricing makes the warrants much more attractive for exercise, potentially injecting approximately $1.8 million into the company. While this move is dilutive and reflects the company's distressed financial state, it represents a critical attempt to secure much-needed capital to extend its operational runway and address ongoing financial challenges, including Nasdaq delisting risks.